Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.20%
#2 aelf aelf +23.92%
#3 Bitway Bitway +21.89%
#4 Decred Decred +16.39%
#5 Starpower Starpower +11.64%
#6 Pons Pons +11.46%
#7 AtomOne AtomOne +10.65%
#8 TRIA TRIA +9.64%
#9 Wibx Wibx +8.12%
#10 Status Status +7.76%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Cell MedX Corp. Cell MedX Corp.

Cell MedX Corp.

CMXC
Rank in Stocks #30402
Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing,... Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing, and marketing both therapeutic and non-therapeutic solutions aimed at individuals suffering from conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and various kidney-related ailments. The company's offerings include the eBalance Pro System, designed for clinical application by medical professionals, and the eBalance Home System, intended for personal use to promote general well-being and alleviate pain. Both systems are managed by the eBalance Console, a central control unit featuring three distinct pre-programmed microcurrent algorithms: wellness, pain management, and a dual mode. Originally established in 2010 as Sports Asylum, Inc., the company adopted its current name, Cell MedX Corp., in September 2014. Its operations are headquartered in Carson City, Nevada.
Share Price
$0.41
Last synced: 2024-12-24
Market Cap
$16.96M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Cell MedX Corp. (CMXC)

Category

Healthcare
Revenue for Cell MedX Corp. (CMXC)
Revenue in Aug 2026 TTM: 0
According to Cell MedX Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cell MedX Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 $46.59B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 $25.84B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 $35.48B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 $21.00B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 $6.51B -
US